{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:06:27Z","timestamp":1792033587074,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1716,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/modpathol.2017.182","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:40:36Z","timestamp":1515742836000},"page":"690-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Myeloproliferative neoplasms with concurrent BCR\u2013ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group"],"prefix":"10.1016","volume":"31","author":[{"given":"Craig R","family":"Soderquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Ewalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Czuchlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia T","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heesun J","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V","family":"Babushok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2017.182_bib1","series-title":"World Health Organization Classification of Tumours","first-page":"29","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1038\/modpathol.2017.182_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12185-009-0471-6","article-title":"A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders","volume":"91","author":"Bee","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1038\/modpathol.2017.182_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1470-2045(07)70295-4","article-title":"Insights into JAK2-V617F mutation in CML","volume":"8","author":"Bocchia","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2017.182_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","article-title":"Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis","volume":"21","author":"Bornhauser","year":"2007","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.182_bib6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","article-title":"JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders","volume":"22","author":"Cambier","year":"2008","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.182_bib7","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.leukres.2009.06.011","article-title":"JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia","volume":"33","author":"Campiotti","year":"2009","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib8","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.leukres.2009.08.009","article-title":"Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation","volume":"34","author":"Caocci","year":"2010","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-008-0131-2","article-title":"Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia","volume":"88","author":"Conchon","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1038\/modpathol.2017.182_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.21296","article-title":"BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome\/myeloproliferative neoplasm (RARS-T)","volume":"84","author":"Gattenlohner","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1038\/modpathol.2017.182_bib11","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood-2013-07-516385","article-title":"Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia","volume":"122","author":"Grisouard","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib12","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2006-12-061135","article-title":"Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation","volume":"109","author":"Hussein","year":"2007","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404591","article-title":"Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia","volume":"21","author":"Inami","year":"2007","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.182_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.52.145","article-title":"Disappearance of both the BCR\/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia","volume":"52","author":"Inokuchi","year":"2012","journal-title":"J Clin Exp Hematop"},{"key":"10.1038\/modpathol.2017.182_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.leukres.2008.03.004","article-title":"Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis","volume":"32","author":"Jallades","year":"2008","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(07)70206-1","article-title":"JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia","volume":"8","author":"Kr\u00e4mer","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2017.182_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0609.2008.01063.x","article-title":"A case of coexistence between JAK2V617F and BCR \/ABL","volume":"81","author":"Pardini","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1038\/modpathol.2017.182_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2162-3619-2-24","article-title":"Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F","volume":"2","author":"Pastore","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1038\/modpathol.2017.182_bib19","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","article-title":"Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation","volume":"9","author":"Pingali","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1038\/modpathol.2017.182_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12288-014-0385-1","article-title":"Coexistence of JAK2V617F mutation and BCR-ABL translocation in a pregnant woman with essential thrombocythemia","volume":"30","author":"Qin","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1038\/modpathol.2017.182_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0609.2010.01458.x","article-title":"Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia","volume":"85","author":"Tefferi","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1038\/modpathol.2017.182_bib22","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s12032-010-9570-8","article-title":"Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera","volume":"28","author":"Toogeh","year":"2011","journal-title":"Med Oncol"},{"key":"10.1038\/modpathol.2017.182_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12185-013-1480-z","article-title":"Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation","volume":"99","author":"Xu","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1038\/modpathol.2017.182_bib24","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/bcj.2015.77","article-title":"Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib","volume":"5","author":"Zhou","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1038\/modpathol.2017.182_bib25","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/ijlh.12010","article-title":"Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis","volume":"35","author":"Cappetta","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1038\/modpathol.2017.182_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","article-title":"Chronic myeloproliferative diseases with concurrent BCR\u2010ABL junction and JAK2V617F mutation","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.182_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PDM.0b013e318246975e","article-title":"Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms","volume":"21","author":"Hummel","year":"2012","journal-title":"Diagn Mol Pathol"},{"key":"10.1038\/modpathol.2017.182_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.leukres.2007.10.018","article-title":"Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders","volume":"32","author":"Kim","year":"2008","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.leukres.2009.01.034","article-title":"A myeloproliferative disorder may hide another one","volume":"33","author":"Laibe","year":"2009","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12185-013-1326-8","article-title":"Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate","volume":"97","author":"Lee","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1038\/modpathol.2017.182_bib31","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.5858\/2007-131-1719-TOPVTC","article-title":"Transformation of polycythemia vera to chronic myelogenous leukemia","volume":"131","author":"Mirza","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/modpathol.2017.182_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3343\/alm.2013.33.3.229","article-title":"Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR\/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment","volume":"33","author":"Park","year":"2013","journal-title":"Ann Lab Med"},{"key":"10.1038\/modpathol.2017.182_bib33","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","article-title":"Concomitant occurrence of BCR-ABL and JAK2V617F mutation","volume":"118","author":"Pieri","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib34","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/j.leukres.2009.09.025","article-title":"A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm","volume":"34","author":"Veronese","year":"2010","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.182_bib35","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","article-title":"BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000331564","article-title":"Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia","volume":"127","author":"Xiao","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1038\/modpathol.2017.182_bib37","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2014-06-585141","article-title":"Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy","volume":"124","author":"Soderquist","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.182_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.13932","article-title":"BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance","volume":"176","author":"Martin-Cabrera","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.182_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1038\/modpathol.2017.182_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.leu.2402912","article-title":"Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies","volume":"17","author":"Clarkson","year":"2003","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.182_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2169\/internalmedicine.41.1183","article-title":"Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL)","volume":"41","author":"Ohsaka","year":"2002","journal-title":"Intern Med"},{"key":"10.1038\/modpathol.2017.182_bib42","first-page":"208","article-title":"P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?","volume":"8","author":"Melo","year":"1994","journal-title":"Leukemia"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017182","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222015034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222015034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/modpathol.2017.182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:48:49Z","timestamp":1760230129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222015034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0893395222015034"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2017.182","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloproliferative neoplasms with concurrent BCR\u2013ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2017.182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}